Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Puzo Michael J

Puzo Michael J trimmed its position in Illumina, Inc. (NASDAQ:ILMN) by 2.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 10,213 shares of the life sciences company’s stock after selling 208 shares during the quarter. Illumina comprises 1.4% of Puzo Michael J’s investment portfolio, making the stock its 29th biggest position. Puzo Michael J’s holdings in Illumina were worth $3,759,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Strategy Asset Managers LLC acquired a new position in shares of Illumina in the 1st quarter worth approximately $26,000. C J Advisory Inc acquired a new position in shares of Illumina in the 1st quarter worth approximately $29,000. Harel Insurance Investments & Financial Services Ltd. acquired a new position in shares of Illumina in the 2nd quarter worth approximately $37,000. Valeo Financial Advisors LLC lifted its holdings in shares of Illumina by 130.0% in the 1st quarter. Valeo Financial Advisors LLC now owns 115 shares of the life sciences company’s stock worth $36,000 after acquiring an additional 65 shares during the last quarter. Finally, Mizuho Securities Co. Ltd. acquired a new position in shares of Illumina in the 1st quarter worth approximately $37,000. Institutional investors own 90.75% of the company’s stock.

In other Illumina news, Director Jay T. Flatley sold 3,300 shares of the stock in a transaction that occurred on Wednesday, May 8th. The shares were sold at an average price of $318.59, for a total value of $1,051,347.00. Following the sale, the director now directly owns 285,816 shares of the company’s stock, valued at approximately $91,058,119.44. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Frances Arnold sold 1,503 shares of the stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $307.95, for a total transaction of $462,848.85. Following the completion of the sale, the director now directly owns 10,159 shares in the company, valued at $3,128,464.05. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 61,167 shares of company stock worth $19,899,477. 0.38% of the stock is owned by insiders.

ILMN traded down $8.01 during trading hours on Monday, hitting $289.37. 625,339 shares of the company’s stock were exchanged, compared to its average volume of 1,782,099. Illumina, Inc. has a 12-month low of $268.62 and a 12-month high of $380.76. The stock’s 50 day moving average price is $335.61. The stock has a market cap of $43.18 billion, a price-to-earnings ratio of 50.59, a P/E/G ratio of 2.77 and a beta of 1.11. The company has a debt-to-equity ratio of 0.42, a quick ratio of 3.33 and a current ratio of 6.79.

Illumina (NASDAQ:ILMN) last announced its earnings results on Monday, July 29th. The life sciences company reported $1.35 earnings per share for the quarter, topping the consensus estimate of $1.32 by $0.03. Illumina had a net margin of 27.56% and a return on equity of 21.73%. The firm had revenue of $838.00 million for the quarter, compared to the consensus estimate of $835.12 million. During the same period in the prior year, the firm earned $1.43 EPS. The firm’s revenue for the quarter was up 1.0% on a year-over-year basis. Analysts predict that Illumina, Inc. will post 6.04 earnings per share for the current fiscal year.

ILMN has been the topic of several recent analyst reports. Deutsche Bank decreased their price objective on shares of Illumina from $290.00 to $280.00 and set a “hold” rating on the stock in a report on Friday, July 12th. Cowen cut their target price on shares of Illumina from $380.00 to $320.00 and set an “outperform” rating on the stock in a research note on Friday, July 12th. Wolfe Research started coverage on shares of Illumina in a research note on Thursday, May 30th. They set an “outperform” rating on the stock. Argus cut their target price on shares of Illumina to $340.00 and set a “buy” rating on the stock in a research note on Thursday, July 18th. Finally, ValuEngine downgraded shares of Illumina from a “buy” rating to a “hold” rating in a research note on Friday, July 19th. One research analyst has rated the stock with a sell rating, four have given a hold rating and eleven have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $330.92.

Illumina Company Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

Featured Article: CBOE Russell 2000® Volatility Index

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.